ReviewExpert review of molecular diagnostics2016
Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma.
Review in Expert review of molecular diagnostics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 42 citations in OpenAlex.
- The impact of the COVID-19 pandemic on the diagnosis, treatment, and prognosis of ovarian cancer in the United States: a retrospective cohort study based on the SEER database.Discover oncology · 2025Article
- Asian Society of Gynecologic Oncology (ASGO) 2024 Annual Meeting in Bali, Indonesia.Journal of gynecologic oncology · 2025Article
- Association of allostatic load with overall survival in epithelial ovarian cancer.Gynecologic oncology · 2024Observational
- Exosomes in Cancer: Diagnostic and Therapeutic Applications.Clinical Medicine Insights. Oncology · 2024Review
- High-grade serous carcinoma of unknown primary origin associated with STIC clinically presented as isolated inguinal lymphadenopathy: a case report.Frontiers in oncology · 2023Article
- Application of Extracellular Vesicles in Gynecologic Cancer Treatment.Bioengineering (Basel, Switzerland) · 2022Review
- LncRNA KCNQ1OT1 promotes the metastasis of ovarian cancer by increasing the methylation of EIF2B5 promoter.Molecular medicine (Cambridge, Mass.) · 2022Article
- Prognostic utility of the ovarian cancer secretome: a systematic investigation.Archives of gynecology and obstetrics · 2022Review
- A Weakly Supervised Deep Learning Method for Guiding Ovarian Cancer Treatment and Identifying an Effective Biomarker.Cancers · 2022Article
- High-grade ovarian cancer associated H/ACA snoRNAs promote cancer cell proliferation and survival.NAR cancer · 2022Article
- Circulating Tumor Cell-Free DNA Genes as Prognostic Gene Signature for Platinum Resistant Ovarian Cancer Diagnosis.Biomarker insights · 2022Article
- Regulation of angiogenesis by microRNAs in cancer.Molecular medicine reports · 2021Review
- High-grade serous cancer of undetermined primary origin presenting as solitary inguinal lymph node enlargement.BMJ case reports · 2021Review
- Exosomes as Biomarkers for Female Reproductive Diseases Diagnosis and Therapy.International journal of molecular sciences · 2021Review
- The involvement of small heat shock protein in chemoresistance in ovarian cancer -EXCLI journal · 2021Article
- Emerging Functions and Clinical Applications of Exosomal ncRNAs in Ovarian Cancer.Frontiers in oncology · 2021Review
- A prognosis-predictive nomogram of ovarian cancer with two immune-related genes:Oncology letters · 2020Article
- Proteomic and lipidomic analysis of exosomes derived from ovarian cancer cells and ovarian surface epithelial cells.Journal of ovarian research · 2020Article
- LEMD1-AS1 Suppresses Ovarian Cancer Progression Through Regulating miR-183-5p/TP53 Axis.OncoTargets and therapy · 2020Article
- CircASH2L Promotes Ovarian Cancer Tumorigenesis, Angiogenesis, and Lymphangiogenesis by Regulating the miR-665/VEGFA Axis as a Competing Endogenous RNA.Frontiers in cell and developmental biology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
introductionOvarian cancer (OvCa) is among the most common types of cancer and is the leading cause of death from gynecological malignancies in western countries. Cancer biomarkers have a potential for improving the management of OvCa patients at every point from screening and detection, diagnosis, prognosis, follow up, response to therapy and outcome. AREAS COVERED: The literature search has indicated a number of candidate biomarkers have recently emerged that could facilitate the molecular definition of OvCa, providing information about prognosis and predicting response to therapy. These potentially promising biomarkers include immune cells and their products, tumor-derived exosomes, nucleic acids and epigenetic biomarkers. Expert commentary: Although most of the biomarkers available today require prospective validation, the development of noninvasive liquid biopsy-based monitoring promises to improve their utility for evaluations of prognosis, response to therapy and outcome in OvCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.